Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To Ring Carbon Of The Additional Six-membered Hetero Ring (e.g., Nicotinic Acid, Etc.) Patents (Class 544/365)
-
Patent number: 6723730Abstract: Disclosed are diaryl piperazines and related compounds of the following Formula: wherein the variables are as defined in the specification. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given.Type: GrantFiled: July 20, 2001Date of Patent: April 20, 2004Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Alan Hutchinson, Robert W. DeSimone, Kevin J. Hodgetts, James E. Krause, Geoffrey G. White
-
Patent number: 6706716Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human &agr;1d adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.Type: GrantFiled: January 17, 2001Date of Patent: March 16, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig
-
Patent number: 6693099Abstract: Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed.Type: GrantFiled: December 19, 2000Date of Patent: February 17, 2004Assignee: The Procter & Gamble CompanyInventors: Charles Raymond Degenhardt, David Joseph Eickhoff
-
Patent number: 6677452Abstract: The present invention relates to novel pyridine carboxamide or sulfonamide derivative compounds of the following formula: wherein R1 to R6 have the meanings provided herein. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing pyridine carboxamide or sulfonamide derivative compounds.Type: GrantFiled: September 30, 1999Date of Patent: January 13, 2004Assignee: Lion Bioscience AGInventors: Yuewu Chen, Hengyuan Lang, Yazhong Pei
-
Patent number: 6660739Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.Type: GrantFiled: June 8, 2001Date of Patent: December 9, 2003Assignee: Eli Lilly and CompanyInventors: Valentine Joseph Klimkowski, Jeffrey Alan Kyle, John Joseph Masters, Michael Robert Wiley
-
Patent number: 6656954Abstract: A sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: November 29, 2001Date of Patent: December 2, 2003Assignee: Pharmacia CorporationInventors: Louis J. Bedell, Joseph J. McDonald, Thomas E. Barta, Daniel P. Becker, Shashidhar N. Rao, John N. Freskos, Brent V. Mischke, Daniel P. Getman, Gary A. DeCrescenzo
-
Patent number: 6653313Abstract: The present invention relates to compounds of the formula wherein each A is independently halo; Y is —(CH2)m—, —C(O)— or —S(O)—; R1 and R2 are independently C1-4 alkyl; R3 is substituted azacycloalkyl etc.; R4 is phenyl substituted at the 2-position with a substituent selected from substituted C1-7 alkyl, substituted C1-7 alkoxy, amine, etc; R5 is hydrogen or C1-4 alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. The present invention also relates to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.Type: GrantFiled: July 11, 2001Date of Patent: November 25, 2003Assignee: Warner-Lambert Company LLCInventors: Mitsuhiro Kawamura, Makoto Kawai, Yuji Shishido, Tomoki Kato, Yasuhiro Katsu, Takafumi Ikeda, Noriaki Murase
-
Patent number: 6638935Abstract: The invention relates to novel pyridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumorsType: GrantFiled: July 20, 2001Date of Patent: October 28, 2003Assignee: Zentaris AGInventors: Peter Emig, Eckhard Günther, Bernhard Kutscher, Bernd Nickel, Jürgen Schmidt, Anita Storch
-
Patent number: 6608060Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.Type: GrantFiled: June 14, 1999Date of Patent: August 19, 2003Assignee: Vertex Pharmaceuticals IncorporatedInventors: Guy W. Bemis, Francesco Gerald Salituro, John Patrick Duffy, John E. Cochran, Edmund Martin Harrington, Mark A. Murko, Keith P. Wilson, Michael Su, Vincent P. Galullo
-
Patent number: 6608196Abstract: Provided are processes for synthesizing structurally diverse pyruvate-derived compounds using a parallel approach on a solid phase support. Examples of such a solid phase support include resins which have also been used in solid phase peptide synthesis.Type: GrantFiled: May 3, 2002Date of Patent: August 19, 2003Assignee: Galileo Pharmaceuticals, Inc.Inventors: Bing Wang, Satyanarayana Janagani, Wyeth B. Callaway, Jonathan L. Sessler
-
Patent number: 6608058Abstract: The present invention relates to novel 6-methylnicotinamide derivatives and their pharmaceutically acceptable salts, the process for preparing them, and the pharmaceutical compositions containing said compounds as active ingredients. The 6-methylnicotinamide derivatives of the present invention exhibit their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV) and hepatitis C virus (HCV), such that they can be used for hepatitis B, hepatitis C and acquired immune deficiency syndrome (AIDS).Type: GrantFiled: October 10, 2002Date of Patent: August 19, 2003Assignee: Dong Wha Pharm. Ind. Co., Ltd.Inventors: Sung-June Yoon, Sang-Wook Lee, Jin-Soo Lee, Nam-Doo Kim, Geun-Hyung Lee, Hak-Dong Lee, Jong-Woo Kim, Sang-Jin Park, Hee-Jeong Park
-
Patent number: 6599890Abstract: A compound of the formula wherein R1, R2 R3, R4 R5, R6, R7, R8, R9 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.Type: GrantFiled: November 8, 2000Date of Patent: July 29, 2003Assignee: Pfizer IncInventors: Kim F. McClure, Mark C. Noe, Michael A. Letavic, Louis S. Chupak
-
Patent number: 6596724Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of oxadiazole, thiadiazole and thiadiazole oxide derivatives of dihydropyridines of Formula I. wherein B is with X being O, S or and X1 is O or S. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.Type: GrantFiled: July 2, 2001Date of Patent: July 22, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Graham S. Poindexter, Mendi Higgins, James Guy Breitenbucher
-
Patent number: 6576764Abstract: The present invention is directed to methods for the preparation of piperazine ring-containing compounds, particularly mirtazapine. According to the present invention, the mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine is made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with a base where the base is present in a ratio of up to about 12 moles of the base per one mole of 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine. The mirtazapine intermediate 1-(3-carboxypyridyl-2)-4-methyl-2-phenyl-piperazine may be made by hydrolyzing 1-(3-cyanopyridyl-2)-4-methyl-2-phenyl-piperazine with potassium hydroxide at a temperature of at least about 130° C.Type: GrantFiled: October 30, 2002Date of Patent: June 10, 2003Assignee: Teva Pharmaceutical Industries LTDInventors: Claude Singer, Anita Liberman, Nina Finkelstein
-
Publication number: 20030060461Abstract: A cyclic diamine compound of formula (1): 1Type: ApplicationFiled: June 29, 2001Publication date: March 27, 2003Applicant: Kowa Co., Ltd.Inventors: Tatsuhiko Kodama, Masahiro Tamura, Toshiaki Oda, Yukiyoshi Yamazaki, Masahiro Nishikawa, Takeshi Doi, Yoshinori Kyotani
-
Patent number: 6531476Abstract: The invention concerns the use of a piperazine derivative of formula (I) wherein: A and B=C═O, C═S or CR7R8 with R7=H, methyl, cyano, cyanomethyl, CO2CH3 or (C═O)CH3 and R8=H or phenyl; R1 to R6=H, OH, or C1-C5 alkoxy; X represents: either C═O, O(C═O), O(C═S), O(SO2), NH(C═O), NH(C═S), NH(SO2), S(C═O) or S(C═S), then Y=NR9R10, CR9R10R11 in which R9, R10 and R11=H, C1-C5 alkyl, C2-C5 alkenyl, or C2-C5 alkynyl or Y=nitrogenous heterocycle comprising 5 to 10 atoms; or X represents O, S, O(C═O)O, NH(C═O)O, or S(C═O)O, then Y=CR9R10R11 with R9, R10, R11 as above; or one of its pharmaceutically acceptable salts for preparing a medicine inhibiting HIV. The invention is useful for treating HIV infection.Type: GrantFiled: March 20, 2001Date of Patent: March 11, 2003Assignees: Universite Paris 7 - Denis Diderot, Commissariat a l'Energie AtomiqueInventors: Francoise Heymans, Nathalie Dereuddre-Bosquet, Jean-Jacques Godfroid, Aazdine Lamouri, Pascal Clayette, Marc Martin
-
Patent number: 6521621Abstract: This invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 1 or 2; ═Q is ═O or ═NR3; X is a covalent bond or a bivalent radical of formula —O—, —S—, —NR3—; R1 is Ar1, Ar1C1-6alkyl or di(Ar1)C1-6alkyl, wherein each C1-6alkyl group is optionally substituted with hydroxy, C1-4alkyloxy, oxo or a ketalized oxo substituent; R2 is Ar2, Ar2C1-6alkyl, Het1 or Het1C1-6alkyl; R3 is hydrogen or C1-6alkyl; L is hydrogen; Ar3; C1-6alkyl; C1-6alkyl substituted with 1 or 2 substituents selected from hydroxy, C1-6alkyloxy, Ar3, Ar3C1-6alkyloxy and Het2; C3-6alkenyl; Ar3C3-6alkenyl; di(Ar3)C3-6alkenyl or a radical of formula (a-1), (a-2), (a-3), (a-4) or (a-5); Ar1, Ar2 and Ar3 are each phenyl or substituted phenyl; Het1 and Het2 are each monocyclic or a bicyclic heterocycles; as substancType: GrantFiled: December 22, 2000Date of Patent: February 18, 2003Assignee: Janssen Pharmaceutica N.V.Inventors: Frans Eduard Janssens, François Maria Sommen, Dominique Louis Nestor Ghislaine Surleraux, Joseph Elisabeth Leenaerts, Yves Emiel Maria Van Roosbroeck
-
Patent number: 6492368Abstract: Novel compounds of the formula I in which X, Y, R1, R2 and R3 are as defined in Patent Claim 1 are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.Type: GrantFiled: March 31, 2000Date of Patent: December 10, 2002Assignee: Merck Patent GmbHInventors: Dieter Dorsch, Hanns Wurziger, Guido Melzer, Horst Juraszyk, Sabine Bernotat-Danielowski
-
Publication number: 20020177594Abstract: Compounds having the formula 1Type: ApplicationFiled: October 26, 2001Publication date: November 28, 2002Inventors: Michael L. Curtin, Yujia Dai, Steven K Davidsen, Robin R. Frey, Yan Guo, Howard R. Heyman, James H. Holms, Zhiqin Ji, Michael R. Michaelides, Anil Vasudevan, Carol K. Wada
-
Patent number: 6479483Abstract: Compounds of the present invention are 4-phenyl-pyridine derivatives with activity as NK-1 receptor antagonists.Type: GrantFiled: July 10, 2001Date of Patent: November 12, 2002Assignee: Hoffmann-La Roche Inc.Inventors: Michael Bös, Quirico Branca, Guido Galley, Thierry Godel, Torsten Hoffmann, Walter Hunkeler, Patrick Schnider, Heinz Stadler
-
Patent number: 6465484Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tryrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.Type: GrantFiled: February 28, 2001Date of Patent: October 15, 2002Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, Randall W. Hungate, April M. Cunningham, Timothy J. Koester
-
Patent number: 6462048Abstract: The present invention relates to lactam derivatives of the formula wherein R1, R2, R3, A, X, Z, n and the dashed line are defined herein, and pharmaceutical compositions thereof, to processes and intermediates for their preparation, and to their medicinal use as selective agonists and antagonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1D receptors. These compounds are useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.Type: GrantFiled: September 24, 1998Date of Patent: October 8, 2002Assignee: Pfizer Inc.Inventor: Harry R. Howard
-
Patent number: 6458793Abstract: The invention relates to heterocyclic derivatives, or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and more accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect, formula (I).Type: GrantFiled: January 28, 2000Date of Patent: October 1, 2002Assignee: Zeneca LimitedInventors: Peter Warner, Roger James, Thorsten Nowak
-
Patent number: 6458790Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment and control of obesity, diabetes, and sexual dysfunction, including erectile dysfunction and female sexual dysfunction.Type: GrantFiled: March 20, 2001Date of Patent: October 1, 2002Assignee: Merck & Co., Inc.Inventors: Brenda L. Palucki, Khaled J. Barakat, Liangqin Guo, Yingjie Lai, Ravi P. Nargund, Min K. Park, Patrick G. Pollard, Iyassu K. Sebhat, Zhixiong Ye
-
Patent number: 6455520Abstract: The invention concerns amide derivatives of formula (I) wherein R3 is (1-6C)alkyl or halogeno; m is 0-3, p is 0-2 and q is 0-4; each of R1 and R2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R4 is a basic group such as amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, di-[(1-6C)alkyl]amino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, heteroaryl, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heterocyclyl, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; and Q2 is a group such as heteroaryl, heteroaryloxy or heteroaryl-(1-6C)alkoxy which is optionally substituted; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.Type: GrantFiled: March 23, 2001Date of Patent: September 24, 2002Assignee: Astra Zeneca ABInventors: Dearg S Brown, George R Brown
-
Patent number: 6448250Abstract: A sulfamato hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: February 7, 2000Date of Patent: September 10, 2002Assignee: G. D. Searle & CompanyInventors: Gary A. DeCrescenzo, Joseph G Rico, Terri Boehm, Jeffery N Carroll, Darren J Kassab, Deborah A Mischke, Shashidhar Rao
-
Patent number: 6448244Abstract: The present invention concerns novel water-soluble azole compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof; as antifungals; their processes for preparation, composition containing them and their use as a medicine.Type: GrantFiled: November 9, 2000Date of Patent: September 10, 2002Assignee: Janssen Pharmaceutica N.V.Inventors: Lieven Meerpoel, Leo Jacobus Jozef Backx, Louis Jozef Elisabeth Van der Veken
-
Patent number: 6444675Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of 4-alkyl and cycloalkyl derivatives of dihydropyridines of Formula I. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.Type: GrantFiled: April 24, 2001Date of Patent: September 3, 2002Assignee: Bristol-Myers Squibb CompanyInventor: Sing-Yuen Sit
-
Patent number: 6432960Abstract: A series of antagonists of NPY have been synthesized and are comprised of squarate derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.Type: GrantFiled: April 24, 2001Date of Patent: August 13, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Sing-Yuen Sit, Graham S. Poindexter
-
Patent number: 6391881Abstract: A series of antagonists of NPY have been synthesized and are comprised of thiourea linked piperazine and piperidine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where Z is NR7R8 or and X is CH or N. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.Type: GrantFiled: April 24, 2001Date of Patent: May 21, 2002Assignee: Bristol-Myers Squibb CompanyInventor: Sing-Yuen Sit
-
Patent number: 6384035Abstract: This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.Type: GrantFiled: October 9, 1998Date of Patent: May 7, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Richard H. Hutchings, Haripada Khatuya, Gee-Hong Kuo, Xiaobing Li, William V. Murray, Catherine Prouty, Frank Villani, Nelson C. F. Yim, Cynthia Maryanoff
-
Patent number: 6340682Abstract: The present invention provides diamide derivatives represented by the following general formula (1): wherein A is a phenyl group or the like, which may be substituted, B is —CH═CH—, —C═C—, —(CH═CH)2—, —C≡C—CH═CH—, —CH═CH—C≡C—, phenylene or the like, and W is or and medicines comprising such a compound. These compounds have an excellent inhibitory effect on the production of an IgE antibody and are hence useful as antiallergic agents and the like.Type: GrantFiled: February 23, 1999Date of Patent: January 22, 2002Assignee: Kowa Co., Ltd.Inventors: Hiroyuki Ishiwata, Mototsugu Kabeya, Hiromichi Shigyo, Masami Shiratsuchi, Yukio Hattori, Hiroshi Nakao, Takao Nagoya, Seiichi Sato, Soichi Oda, Makoto Suda, Manabu Shibasaki
-
Patent number: 6331545Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.Type: GrantFiled: December 17, 1999Date of Patent: December 18, 2001Inventors: Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
-
Patent number: 6326371Abstract: The present invention relates to a method for treating a patient suffering from a mental disorder, comprising administering to the patient an effective 5-HT1A agonistic and 5-HT2 antagonistic amount of a compound having the formula (I): or a pharmacologically active salt thereof.Type: GrantFiled: October 4, 1996Date of Patent: December 4, 2001Assignee: Pharmacia AktiebolagInventors: Lisbeth Abramo, Torbjörn Lundstedt, Curt Nordvi, Knut Gunnar Olsson, Martin Brodszki
-
Patent number: 6323229Abstract: A compound of the formula wherein m, R1, R2, R3, R4, R5 and X are as defined, useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.Type: GrantFiled: April 14, 1999Date of Patent: November 27, 2001Assignee: Pfizer INCInventor: Harry R. Howard
-
Patent number: 6323227Abstract: This invention relates to compounds of formula which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.Type: GrantFiled: February 26, 1999Date of Patent: November 27, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Scott I. Klein, Kevin R. Guertin, Alfred P. Spada, Heinz W. Pauls, Yong Gong, Daniel G. McGarry
-
Patent number: 6316445Abstract: The present invention relates to novel carboxy substituted acyclic carboxamide derivatives of formula (1)): and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis.Type: GrantFiled: May 6, 1999Date of Patent: November 13, 2001Assignee: Aventis Pharmaceuticals Inc.Inventors: Timothy P. Burkholder, George D. Maynard, Elizabeth M. Kudlacz
-
Patent number: 6316617Abstract: This invention encompasses compounds of the formula where X1, X2, and X3, independently represent substituents of formula and the pharmaceutically acceptable salts thereof wherein the remaining variables are as defined herein and wherein said compounds are useful in the diagnosis and treatment of feeding disorders such as obesity and bulimia and cardiovascular diseases such as essential hypertension and congestive heart failure due to the binding of these compounds to human Neuropeptide Y1 receptors.Type: GrantFiled: August 8, 2000Date of Patent: November 13, 2001Assignee: Neurogen CorporationInventors: Charles A. Blum, Robert DeSimone, Alan Hutchison, John M. Peterson
-
Patent number: 6306860Abstract: Anti-viral agents of formula (1) have been identified. Their preparation method is described. These 2,5-pyridinedicarboxylic acid derivatives or their pharmaceutically acceptable salts are useful in countering the proliferation of viruses such as hepatitis B virus and human immunodeficiency virus.Type: GrantFiled: November 7, 2000Date of Patent: October 23, 2001Assignee: Dong Wha Pharm. Inc. Co., Ltd.Inventors: Sung Joon Yoon, Sang Wook Lee, Hyeong Su Sim, Yong Kyun Park, Wang Yong Yang, Jong Woo Kim, Jae Jin Han, Je In Yoon, Sang Jin Park, Hee Jeoung Park, Dong Hyuk Sin, Hwan Bong Chang
-
Patent number: 6306859Abstract: Compounds of the Formula (I) wherein R2, Y, X and n are as defined in the specification which compounds are useful in the treatment of disorders associated with serotonergic neuron-related diseases.Type: GrantFiled: March 1, 2000Date of Patent: October 23, 2001Assignee: American Home Products CorporationInventors: Wayne E. Childers, Michael G. Kelly, Gan Zhang, Yvette L. Palmer, Edward J. Podlesny
-
Patent number: 6297375Abstract: The compounds of the related invention are related to 4-phenyl-pyridine derivatives connected by a bridge containing oxygen or nitrogen to a phenyl derivative.Type: GrantFiled: February 22, 2000Date of Patent: October 2, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Michael Bös, Quirico Branca, Guido Galley, Thierry Godel, Torsten Hoffmann, Walter Hunkeler, Patrick Schnider, Heinz Stadler
-
Patent number: 6281214Abstract: A biphenyl derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof: wherein R1, R2, R3, R4, and R5 are defined in the specification, is clinically useful for treating and ameliorating mental disorders such as cerebrovascular disorder, aggressive behavior due to senile dementia, mental excitation, poriomania, delirium, hallucination, hyperkinesia, schizophrenia, emotional disturbance, depression, neurosis, psychophysiologic disorder and anxiety neurosis. The compounds exhibit dopamine 2 receptor antagonism and/or serotonin 2 receptor antagonism.Type: GrantFiled: October 5, 1998Date of Patent: August 28, 2001Assignee: Eisai Co., LtdInventors: Kozo Akasaka, Masahiro Yonaga, Akiharu Kajiwara, Kunizo Higurashi, Kohshi Ueno, Satoshi Nagato, Makoto Komatsu, Noritaka Kitazawa, Masataka Ueno, Yoshiharu Yamanishi, Yoshimasa Machida, Yuki Komatsu, Naoyuki Shimomura, Norio Minami, Toshikazu Shimizu, Atsushi Nagaoka
-
Patent number: 6218396Abstract: This invention relates a to a series of heterocyclic substituted piperazines of Formula I methods of treatment, pharmaceutical compositions containing them, and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.Type: GrantFiled: February 18, 1999Date of Patent: April 17, 2001Assignee: Orth-McNeil Pharmaceutical, Inc.Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty
-
Patent number: 6218394Abstract: 4-Aryl-1-(indanmethyl, dihydrobenzofuramethyl or dihydrobenzothiophenemethyl) piperidine, -tetrahydropyridine or -piperazine compounds of general formula (I) wherein one of X and Y is CH2, and the other one is CH2, O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R1 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, a group R9VCO— where V is O or S and R9 is alkyl or aryl, or a group R10R11NCO— or R10R11NCS— wherein R10 and R11 are hydrogen, alkyl or aryl, or R10 and R11 are linked to form a ring; R2 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl; or R1 and R2 are linked to form a ring; R3-R5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylalkyl or nitro; R6 and R7 are hydrogen or alkyl or they are linked to constitute a 3-7-membered ring; R8 is hydrogen or alkylType: GrantFiled: December 9, 1996Date of Patent: April 17, 2001Assignee: H. Lundbeck A/SInventors: Jens Kristian Perregaard, John Willie Stenberg, Bitten Hansen
-
Patent number: 6211242Abstract: This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by the general formula (I): wherein R1 is aryl optionally substituted with lower alkyl, etc., R2 is lower alkyl, etc., R3 is hydrogen, etc., R4 is aryl, etc., X is CH or N, and Y is CH or N, and pharmaceutically acceptable salts thereof, to processes for the preparation thereof and to a pharmaceutical composition comprising the same.Type: GrantFiled: January 30, 1998Date of Patent: April 3, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroyuki Setoi, Takehiko Ohkawa, Tatsuya Zenkoh, Keiji Hemmi, Hirokazu Tanaka
-
Patent number: 6200978Abstract: Compounds of the formula (I)—shown below—are described. The compounds are useful in the manufacture of a pharmaceutical composition for preventing or treating inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel disease, disorders of respiratory function, gastrointestinal disorders such as functional bowel disease, functional GI disorders such as irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, non-ulcerogenic dyspepsia or others associated with disorders of motility or secretion, urogenital tract disorders such as incontinence, as analgesics for treating pain including non-somatic pain, or as immunosuppressants to prevent rejection in organ transplant and skin graft.Type: GrantFiled: March 3, 1999Date of Patent: March 13, 2001Assignee: Pfizer Inc.Inventors: Graham Nigel Maw, Donald Stuart Middleton
-
Patent number: 6197772Abstract: This invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, as substance-P antagonists; their preparation, compositions containing them and their use as a medicine.Type: GrantFiled: April 3, 1998Date of Patent: March 6, 2001Assignee: Janssen Pharmaceutica N.V.Inventors: Frans Eduard Janssens, François Maria Sommen, Dominique Louis Nestor Ghislaine Surleraux, Joseph Elisabeth Leenaerts, Yves Emiel Maria Van Roosbroeck
-
Patent number: 6191145Abstract: Orally-active nipecotamide glycolamide ester derivatives of formula (I): are disclosed as useful in treating platelet-mediated thrombotic disorders.Type: GrantFiled: October 29, 1999Date of Patent: February 20, 2001Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventor: William J. Hoekstra
-
Patent number: 6162804Abstract: The present invention relates to benzinidazole compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.Type: GrantFiled: March 11, 1999Date of Patent: December 19, 2000Assignee: Merck & Co., Inc.Inventors: Mark T. Bilodeau, April M. Cunningham, Randall W. Hungate, Timothy J. Koester
-
Patent number: RE37886Abstract: This invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, as substance-P antagonists; their preparation, compositions containing them and their use as a medicine.Type: GrantFiled: August 23, 2001Date of Patent: October 15, 2002Assignee: Janssen Pharmaceuticals, N.V.Inventors: Frans E. Janssens, François M. Sommen, Dominique L. N. G. Surleraux, Joseph E. Leenaerts, Yves E. M. Van Roosbroeck